Odyssey Therapeutics (NASDAQ:ODTX) Now Covered by Oppenheimer

Investment analysts at Oppenheimer assumed coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX) in a report issued on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $40.00 price target on the stock. Oppenheimer’s target price would indicate a potential upside of 135.85% from the company’s previous close.

ODTX has been the subject of several other reports. TD Cowen began coverage on Odyssey Therapeutics in a research note on Tuesday. They issued a “buy” rating for the company. Wall Street Zen raised Odyssey Therapeutics to a “hold” rating in a research note on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $40.00.

Odyssey Therapeutics Stock Performance

NASDAQ ODTX opened at $16.96 on Tuesday. Odyssey Therapeutics has a 1-year low of $15.35 and a 1-year high of $20.30.

Insider Activity at Odyssey Therapeutics

In other news, Director Nan (Ln) Li acquired 1,111,111 shares of Odyssey Therapeutics stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $19,999,998.00. Following the acquisition, the director directly owned 3,333,516 shares of the company’s stock, valued at $60,003,288. This trade represents a 50.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the insider directly owned 1,831,383 shares in the company, valued at approximately $32,964,894. This trade represents a 43.54% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 4,183,777 shares of company stock worth $75,319,986 over the last three months.